Engineered immune cells take on tough gut cancers in new trial
Disease control
Recruiting now
This study tests a new treatment called CHM-2101 for people with advanced gastrointestinal cancers (stomach, colon, rectal, or neuroendocrine tumors) that have stopped responding to standard therapies. The treatment uses the patient's own immune cells, which are modified in a lab…
Phase: PHASE1, PHASE2 • Sponsor: Chimeric Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC